Intracranial Metastasis of Esthesioneuroblastoma May Occur 19 Years After Remission
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
There are several steps health care providers can take to help patients with CNS cancers navigate the disability application process.
Tovorafenib produced responses in young patients with progressive or recurrent BRAF-altered low-grade glioma in a phase 2 trial.
The sequence of treatment with rolapitant and ondansetron does not appear to impact chemoradiation-induced nausea and vomiting.
About 1 in 10 patients with high-grade glioma had a palliative care consultation before the end-of-life phase, researchers found.